{"id":"NCT00362648","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Developing World Study for RotaTeq™ (V260-015)(COMPLETED)","officialTitle":"Efficacy, Safety, and Immunogenicity of RotaTeq™ Among Infants in Asia and Africa","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-03","primaryCompletion":"2009-03","completion":"2009-03","firstPosted":"2006-08-10","resultsPosted":"2010-05-13","lastUpdate":"2017-04-13"},"enrollment":7504,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Vomiting","Diarrhea","Fever"],"interventions":[{"type":"BIOLOGICAL","name":"RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent","otherNames":["RotaTeq™","V260"]},{"type":"BIOLOGICAL","name":"Comparator: Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the current study is to evaluate whether the vaccine is effective, well-tolerated and immunogenic among infants in developing countries.","primaryOutcome":{"measure":"Occurrence of Severe Clinical Rotavirus Disease Caused by Any Rotavirus Serotype More Than 14 Days Following the Third Dose","timeFrame":"At least 14 days following the third vaccination","effectByArm":[{"arm":"RotaTeq™ - Africa","deltaMin":79,"sd":null},{"arm":"Placebo - Africa","deltaMin":129,"sd":null},{"arm":"RotaTeq™ - Asia","deltaMin":38,"sd":null},{"arm":"Placebo - Asia","deltaMin":71,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG002 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"4 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["29564996","27755463","20692031","20692030"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":144,"n":3744},"commonTop":["Pyrexia","Cough","Diarrhoea","Rhinitis","Rash"]}}